Country Club Bank Buys 29 Shares of Stryker Corporation $SYK

Country Club Bank increased its stake in Stryker Corporation (NYSE:SYK) by 0.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,103 shares of the medical technology company’s stock after buying an additional 29 shares during the quarter. Country Club Bank’s holdings in Stryker were worth $2,402,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of SYK. Goodman Advisory Group LLC purchased a new stake in shares of Stryker during the first quarter valued at $32,000. City Holding Co. boosted its stake in shares of Stryker by 528.6% during the first quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock valued at $33,000 after purchasing an additional 74 shares during the period. Ridgewood Investments LLC raised its holdings in shares of Stryker by 48.4% in the second quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after acquiring an additional 30 shares in the last quarter. Ransom Advisory Ltd purchased a new stake in Stryker in the first quarter worth about $37,000. Finally, Smallwood Wealth Investment Management LLC purchased a new stake in Stryker in the first quarter worth about $40,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Performance

SYK opened at $369.14 on Wednesday. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The company has a quick ratio of 1.06, a current ratio of 1.78 and a debt-to-equity ratio of 0.70. The company has a market cap of $141.12 billion, a P/E ratio of 48.89, a price-to-earnings-growth ratio of 2.64 and a beta of 0.94. The firm’s 50-day moving average price is $381.50 and its 200-day moving average price is $378.86.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker’s dividend payout ratio is currently 44.50%.

Analysts Set New Price Targets

A number of research firms recently weighed in on SYK. Rothschild & Co Redburn began coverage on shares of Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price objective for the company. Weiss Ratings reiterated a “buy (b-)” rating on shares of Stryker in a report on Saturday, September 27th. Redburn Partners set a $420.00 target price on shares of Stryker in a report on Thursday, September 18th. Wells Fargo & Company boosted their target price on shares of Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Finally, BTIG Research reiterated a “buy” rating on shares of Stryker in a report on Monday, July 14th. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average price target of $430.10.

Insider Buying and Selling

In other news, insider Viju Menon sold 500 shares of the firm’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the sale, the insider owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.